期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 211, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2020.113027
关键词
Melatonin; N-salicylic acid; Inflammation-associated cancer; STAT3
资金
- Recruitment Program of Global Experts (1000 Talents Plan)
- Fundamental Research Funds for the Central Universities [lzujbky-2019-ct08]
- Young Scientists Fund of National Natural Science Fund [81903844]
By modifying melatonin and salicylic acid, a new compound P-3 was created with the ability to inhibit the connection between inflammation and cancer, making it a promising chemical structure for developing novel anti-cancer agents.
The combination between two well-studied bioactive compounds melatonin and salicylic acid with proper modifications unexpectedly creates a sharp pair of scissors cutting off the vicious connection between inflammation and cancer by targeting a key contributor Signal Transducers and Activators of Transcription 3 (STAT3) in the two pathological processes. A representative compound P-3 with IC50 values on each tested cell line ranging from 7.37 to 18.62 mu M among the designed melatonin derivatives is equipped with the ability of curbing inflammation-promoting cancer by down-regulating the expression, activation and nuclear translocation of STAT3, breaking the feedforward loop of STAT3 activation by decreasing the expression of pro-tumorigenic cytokines, and inducing cell apoptosis through ROS triggered Cyto-c/Caspase-3 pathway. This study suggests that the melatonin derivative P-3 is likely to become a promising chemical structure for developing the novel anti-cancer agents taking effect through hindering the mutual-promoting processes between inflammation and cancer. (C) 2020 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据